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Estimating the burden of neural tube defects 
in low– and middle–income countries
Background To provide an estimate for the burden of neural tube 
defects (NTD) in low– and middle–income countries (LMIC) and ex-
plore potential public health policies that may be implemented. Al-
though effective interventions are available to prevent NTD, there is 
still considerable childhood morbidity and mortality present in LMIC.
Methods A search of Medline, EMBASE, Global Health Library and 
PubMed identified 37 relevant studies that provided estimates of the 
burden of NTD in LMIC. Information on burden of total NTD and 
specific NTD types was separated according to the denominator into 
two groups: (i) estimates based on the number of live births only; and 
(ii) live births, stillbirths and terminations. The data was then extract-
ed and analysed.
Results The search retrieved NTD burden from 18 countries in 6 
WHO regions. The overall burden calculated using the median from 
studies based on livebirths was 1.67/1000 (IQR = 0.98–3.49) for total 
NTD burden, 1.13/1000 (IQR = 0.75–1.73) for spina bifida, 0.25/1000 
(IQR = 0.08–1.07) for anencephaly and 0.15/1000 (IQR = 0.08–0.23) 
for encephalocele. Corresponding estimates based on all pregnancies 
resulting in live births, still births and terminations were 2.55/1000 
(IQR = 1.56–3.91) for total NTD burden, 1.04/1000 (IQR = 0.67–
2.48) for spina bifida, 1.03/1000 (IQR = 0.67–1.60) for anencephaly 
and 0.21 (IQR = 0.16–0.28) for encephalocele. This translates into 
about 190 000 neonates who are born each year with NTD in LMIC.
Conclusion Limited available data on NTD in LMIC indicates the 
need for additional research that would improve the estimated bur-
den of NTD and recommend suitable aid policies through maternal 
education on folic acid supplementation or food fortification.
Every year, more than 300 000 children are born with neural tube defects 
(NTD) [1-6]. NTD are a group of congenital abnormalities that still cause 
hundreds of thousands of deaths in 0–4 years age group, while similar 
number of surviving children remain disabled for life [1-6]. One of the 
Millennium Development Goals initiated by the United Nations was ded-
icated to reducing global mortality rates of children in this age group. 
Since 1990, global child mortality has been declining largely due to the 
focus on communicable diseases, which included the expansion of im-
munisation programmes, promotion of breast–feeding and increased pro-
vision of mosquito bednets in many countries worldwide [2]. This reduc-
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METHODS
A systematic literature review was conducted to search for 
published literature regarding population–based NTD bur-
den estimates in LMIC, through the use of electronic data-
bases:  Medline,  Embase,  Global  Health  Library  and 
PubMed. Potential further data were searched for on 
Google Scholar and by crosschecking reference lists from 
review articles. The search used Medical Subject Headings 
(MeSH) and key words for the burden of NTD in LMIC, as 
outlined by the World Bank. Limits of “human” and “2000–
current” were used to obtain the most up to date NTD bur-
den information. The last searches of the four databases 
were conducted on 6 February 2013. Search terms for 
Medline are shown in Table 1 and were modified for oth-
er databases as required.
tion of mortality has led to the neglected causes of child 
mortality to be exposed, including that of congenital ab-
normalities [3-6].
NTD are one of the most common presenting birth defects, 
arising as a result of incomplete closure of the brain or spi-
nal cord in the 3rd and/or 4th week of pregnancy [3]. NTD 
can be classified as open or closed, depending on whether 
neural tissues are exposed or covered by skin, respectively. 
Open NTD are more frequent and include spina bifida, an-
encephaly and encephalocele. Closed NTD, such as teth-
ered cord syndrome, are less frequent in comparison [4].
The best known risk factor for foetal NTD is maternal folate 
deficiency, arising from low levels of vitamin B9 (folic acid) 
[7,8]. Maternal vitamin B12 deficiency has only recently 
been shown to independently contribute to risk of NTD 
[9,10]. Additional risk factors for NTD development in-
clude a positive family history, smoking and indoor air pol-
lution from coal and biomass heating used predominantly 
in developing countries [11-15]. Moreover, NTD are related 
to maternal socio–economic status, education, area of resi-
dence, and maternal nutrient deficiency or obesity [16,17].
NTD can be identified through simple prenatal testing us-
ing ultrasound imaging or maternal serum alpha–fetopro-
tein (MSAFP) level screening [18]. Abnormal elevation of 
MSAFP is a relatively specific and sensitive test for detec-
tion of NTD [18]. The abnormal presence of acetylcholin-
esterases (AChE) in amniotic fluid determined through am-
niocentesis  can  also  be  used  for  screening  of  NTD. 
However, a higher–than–normal test result is often not di-
agnostic and further evaluation should always be under-
taken [19,20].
Since the discovery of folic acid as an effective intervention 
for prevention of neural tube defects [21], many countries 
have recommended folic acid intake before conception and 
during pregnancy. However, the dramatic 20% decrease in 
NTD birth burden after mandatory folic acid fortification 
(FAF) of enriched products in the US in 1998 showed that 
there may be more practical ways to administer this inter-
vention [22]. Since this example, many countries such as 
Chile, Saudi Arabia and South Africa have implemented sim-
ilar measures to staple food [23-25]. Despite folic acid being 
a well–known, cost–effective intervention, many developing 
countries continue to have either ineffective or no policy to 
increase maternal uptake of folic acid to prevent NTD.
The aims and objectives of this systematic review were:
1.   To provide an estimate of NTD burden in LMIC by 
systematically reviewing literature available in pub-
lic domain;
2.   To examine and discuss the significance of these find-
ings and consider clinical and cost–effective inter-
ventions and health policies with regards to NTD.
Table 1. Search terms for Medline
1. exp Developing Countries/
2. Developing countr*.tw
3. (developing adj3 countr*).tw
4. africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or moroc-
co/ or tunisia/ or “africa south of the sahara”/ or africa, central/ or 
cameroon/ or central african republic/ or chad/ or congo/ or “dem-
ocratic republic of the congo”/ or equatorial guinea/ or gabon/ or 
africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or 
kenya/ or rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ 
or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ 
or mozambique/ or namibia/ or south africa/ or swaziland/ or zam-
bia/ or zimbabwe/ or benin/ or burkinafaso/ or cape verde/ or cote 
d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea–bissau/ or li-
beria/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or 
sierra leone/ or togo/ or americas/ or caribbean region/ or west in-
dies/ or “antigua and barbuda”/ or bahamas/ or barbados/ or cuba/ 
or dominica/ or dominican republic/ or grenada/ or guadeloupe/ 
or haiti/ or jamaica/ or martinique/ or netherlandsantilles/ or puer-
torico/ or “saint kitts and nevis”/ or saint lucia/ or “saint vincent 
and the grenadines”/ or “trinidad and tobago”/ or central america/ 
or belize/ or costa rica/ or el salvador/ or guatemala/ or honduras/ 
or nicaragua/ or panama/ or panama canal zone/ or latinamerica/ 
or mexico/ or south america/ or argentina/ or bolivia/ or brazil/ or 
chile/ or colombia/ or ecuador/ or frenchguiana/ or guyana/ or 
paraguay/ or peru/ or suriname/ or uruguay/ or venezuela/ or ka-
zakhstan/ or kyrgyzstan/ or tajikistan/ or turkmenistan/ or uzbeki-
stan/ or borneo/ or brunei/ or cambodia/ or east timor/ or indone-
sia/ or laos/ or malaysia/ or mekong valley/ or myanmar/ or 
philippines/ or thailand/ or vietnam/ or bangladesh/ or bhutan/ or 
india/ or sikkim/ or middle east/ or afghanistan/ or iran/ or iraq/ 
or israel/ or jordan/ or lebanon/ or saudiarabia/ or syria/ or turkey/ 
or united arab emirates/ or yemen/ or nepal/ or pakistan/ or sril-
anka/ or far east/ or china/ or tibet/ or “democratic people's repub-
lic of korea”/ or mongolia/ or taiwan/ or albania/ or lithuania/ or 
bosnia–herzegovina/ or bulgaria/ or “macedonia (republic)”/ or 
moldova/ or montenegro/ or romania/ or russia/ or bashkiria/ or 
dagestan/ or moscow/ or siberia/ or serbia/ or ukraine/ or armenia/ 
or atlantic islands/ or azores/ azerbaijan/ or “georgia (republic)”/ 
or comoros/ or madagascar/ or mauritius/ or seychelles/ or vanu-
atu/ or micronesia/ or palau/ or expsamoa/ or americansamoa/ or 
“independent state of samoa”/ or tonga/
5. exp neural tube defects/ or anencephaly/ or arnold–chiari malfor-
mation/ or encephalocele/ or meningocele/ or meningomyelocele/ 
or “pentalogy of cantrell”/ or exp spinal dysraphism/ or nervous 
system malformation
6. “neural tube defect”.tw
7. “neural tube defects”.tw
8. NTD.tw
9. exp Prevalence/
10. prevalen*.tw
11. 1 or 2 or 3 or 4
12. 5 or 6 or 7 or 8
13. 9 or 10
14. 11 and 12 and 13
15. Limit 14 to (humans and yr = ”2000 –Current”)
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Study selection
The inclusion criteria for relevant papers included popula-
tion or hospital based studies conducted in LMIC, which 
were geographically defined taking into account both the 
World Health Organization's and the World Bank's classi-
fication and treating any discrepancies in an inclusive, rath-
er than exclusive way. The studies needed to have clearly 
expressed NTD burden showing a denominator, published 
between 2000 and 2013. The searches were limited to the 
period after the year 2000 in order to generate an estimate 
that is reflective of reasonably recent NTD trends. No lim-
it on language and publication type was set. Keeping in 
mind that many babies with NTD are stillborn or termi-
nated through miscarriages and abortions, we decided to 
include studies with live births, stillbirths and terminations 
as a separate body of evidence, in addition to studies that 
used live births–based denominators to report the burden 
of NTD.
Studies conducted solely in specialist hospital units were 
excluded, as they are likely to report a burden enriched for 
severe cases that would not be representative of the gen-
eral population. Studies with incomplete data or where 
NTD burden could not be calculated were also excluded.
Data extraction
For the 37 retained studies, relevant data were extracted 
and compiled into Microsoft Excel spreadsheets. Data in-
cluding authors, country, study size and diagnostic criteria 
for specific NTD type and total NTD cases were extracted. 
Types of NTD included spina bifida, myelomeningocele, 
meningocele, anencephaly, encephalocele and “other NTD 
types”. Burden was expressed using the number of cases 
observed and a total sample of live births (or, alternatively, 
a total sample of live births, stillbirths and terminations).
Data analysis
When the number of affected children was not specifically 
provided in the study, it was calculated with the sample 
population using the following equation:
Estimated NTD burden = Number of observed NTD cases/
Sample size (eg, number of live births) × 1000
The estimates of the burden provided in the retained stud-
ies were separated into two categories: those in which the 
denominator was based on the number of live births, and 
the other group in which live births, stillbirths and termi-
nations were all included. Wherever this information was 
available for both categories, figures were separately added 
to the respective groups. The median estimate of the NTD 
burden and the inter–quartile range (IQR) for all LMIC re-
gions was then determined, based on the retained 37 stud-
ies. Eventually, the median was multiplied by the number 
of livebirths in LMIC in the year 2010, according to UN 
Population Division's estimates (www.un.org/esa/popula-
tion/), to determine the absolute number of NTD cases that 
has been introduced to the LMIC in 2010.
RESULTS
A review of relevant databases performed independently 
by two researchers (AL and SS) identified a total of 3339 
studies, but only 37 satisfied all criteria for inclusion (as 
shown in Figure 1). Of the retained studies, 20 reported 
NTD rates in live births only, 14 reported rates in live 
births, stillbirths and terminations combined, and 3 stud-
ies reported both.
The median sample size from all reviewed papers was 
36 331, which corresponded well to a typical study size. 
The median sample population in studies based on live 
births was 35 974, compared to 49 534 in studies based on 
live births, stillbirths and terminations.
The search retrieved NTD burden from 18 countries in 6 
WHO regions (Table 2). The overall burden calculated us-
ing the median from studies based on live births was 
1.67/1000 (IQR = 0.98–3.49) for total NTD burden (Table 
3 and 4), 1.13/1000 (IQR = 0.75–1.73) for spina bifida (Ta-
ble 3 and 5), 0.25/1000 (IQR = 0.08–1.07) for anencephaly 
(Table 3 and 6) and 0.15/1000 (IQR = 0.08–0.23) for en-
cephalocele (Table 3 and 7).Corresponding estimates based 
on all pregnancies resulting in live births, still births and ter-
minations were 2.55/1000 (IQR = 1.56–3.91) for total NTD 
burden (Table 3 and 8), 1.04/1000 (IQR = 0.67–2.48) for 
spina bifida (Table 3 and 9), 1.03/1000 (IQR = 0.67–1.60) 
for anencephaly (Table 3 and 10) and 0.21 (IQR = 0.16–
0.28) for encephalocele (Table 3 and 11). This translates 
into about 190 000 neonates who are born each year with 
NTD in LMICs.
Figure 1. A summary of the process of literature search.
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Table 2. Distribution of retained studies by WHO regions
Number of studies
WHo regioN CouNtry total 
studies
live 
birtHs 
oNly
live birtHs, 
stillbirtHs & 
termiNatioNs
Western Pacific China 6 1 5
Malaysia 1 0 1
South East Asia
India 3 2 1
Pakistan 1 1 0
Thailand 1 1 0
Eastern Mediterranean
Jordan 2 2 0
Saudi Arabia 2 2 0
Iran 4 1 3
Europe
Azerbaijan 1 0 1
Russia 1 1 0
Ukraine 1 0 1
Turkey 3 2 1
Africa Cameroon 1 1 0
South Africa 1 1 0
Americas
Brazil 3 2 1
Colombia 1 1 0
Peru 1 1 0
Chile 4 1 3
Table 3. A summary of estimates of the burden of neural tube defects and its sub–types from 37 retained studies from low and 
middle–income countries
studied outCome deNomiNator Number of studies mediaN (per 1000) iNter–quartile raNge (per 1000) miNimum(per 1000) maximum (per 1000)
All neural tube defects LB 23 1.67 0.98–3.49 0.50 12.41
LB+SB+TP 17 2.55 1.56–3.91 0.86 19.94
Spina bifida LB 14 1.13 0.75–1.73 0.38 5.90
LB+SB+TP 15 1.04 0.67–2.48 0.35 5.81
Anencephaly LB 13 0.25 0.08–1.07 0.01 11.33
LB+SB+TP 16 1.03 0.67–1.60 0.30 8.26
Encephalocele LB 9 0.15 0.08–0.23 0.03 0.39
LB+SB+TP 13 0.21 0.16–0.28 0.07 2.65
LB – live births; LB+SB+TP – live births, stillbirths and terminated pregnancies
Table 4. Studies that reported rates for total NTD burden based 
on live births only
autHor aNd refereNCe sample size Cases rate (per 1000 live birtHs)
Amarin et al. [26] 61 447 16 0.95
Aqrabawi [11] 5088 33 6.50
Asindi et al. [27] 82 176 64 0.78
Bademci et al. [28] 5499 17 3.09
Behrooz et al. [29] 13 262 56 4.22
Chen et al. [30] 26 599 48 1.80
Cherian et al. [31] 1218 10 8.21
Cortes et al. [32] 59 627 67 1.12
Costa et al. [33] 9386 11 1.17
Gu et al. [13] 6420 25 3.89
Hertrampf et al. [34] 117 740 114 0.97
Kaur et al. [35] 7400 5 0.68
Khattak et al. [36] 5560 69 12.41
Mandiracioglu et al. [37] 36 331 56 1.54
Njamnshi et al. [38] 52 710 98 1.86
Pachajoa et al. [39] 32 995 55 1.67
Petrova et al. [40] 141 159 298 2.11
Pacheco et al. [41] 24 964 124 4.97
Ricks et al. [42] 35 974 72 2.00
Safdar et al. [24] 33 489 42 1.25
Sayed et al. [25] 46 021 45 0.98
Wasant et al. [43] 180 000 114 0.63
Yuskiv et al. [33] 75 609 38 0.50
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As expected, when comparing IQRs as the robust predic-
tions, overall NTD burden estimates were found to be high-
er in the live births, stillbirths and terminations group in 
comparison to studies that included only live births, while 
spina bifida was the most commonly reported NTD type. 
Moreover, there is internal consistency in the presented es-
timates, because the sum of the specific NTD types always 
fits into the “envelope” of all NTDs.
DISCUSSION
This systematic literature review aimed to examine the bur-
den of NTD in LMIC. It is, to our knowledge, the first study 
to quantitatively estimate the total NTD burden in LMIC. 
As such, the burden estimates can be successfully used in 
the much–needed preventive policy development in LMIC 
with high risk of NTD.
The results from the 37 selected studies [10-13,23-55] sug-
gest that NTD burden is approximately twice as high, if not 
higher, in LMIC than in high–income countries [56-58]. 
The findings from live birth–only studies showed that the 
median total NTD burden is 1.67 per 1000 live births, al-
though there were reports of significantly higher values, 
with a maximum burden as high as 12.41/1000. The over-
all median is greater in studies where live births, stillbirths 
and terminations were taken into account, where the bur-
den is 2.55 per 1000 and maximum reported burden of 
19.94/1000. This is expected, as a considerable proportion 
of NTD result in stillbirths and terminations [59,60].
Significant discrepancies between reported burdens from 
the same country were sometimes observed. These differ-
ences were attributed to different study settings, for example 
in rural and urban India [31,35,45], or different time peri-
ods as seen in two studies from Jordan [11,26]. Extremely 
high burden of NTD of 13.79 and 19.94 was observed in 
two studies from China, although the samples were rather 
small, indicating a possible selection bias [10,13].
Regardless of the progress in control of NTDs observed in 
high–income countries, NTD continue to be a problem of 
significant public health impact in LMIC. NTD have detri-
mental physical and emotional effects on the affected chil-
dren and their caregivers, and may present a life–long im-
portant and often insurmountable economic problem, 
especially to poor families [52]. The cost of raising a child 
with spina bifida from birth to 18 years of age in Chile was 
estimated to be around US$ 120 000 [34]. These expenses, 
apart from causing individual deprivation, are a significant 
economic burden on the level of the whole society, causing 
a vicious circle of poverty in the LMIC.V
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Hundreds of thousands of live born babies are affected by 
NTD in LMIC, which remain an important and preventable 
cause of morbidity and mortality. Thus, effective policies for 
prevention are vital to reduce the burden of NTD on indi-
viduals and on society. Up to now, more than 59 countries 
have committed to mandatory fortification programmes 
[59,61,62]. However, many LMIC still have ineffective rec-
ommendations and policies towards folic acid uptake. Some 
countries have recommended the improvement of daily diet 
and folic acid supplement use, but do not have a manda-
tory policy [59,61,62]. Recommendation provides a good 
starting point for reducing NTD burden in LMIC. However, 
many households in LMIC may not be able to afford folic 
acid supplementation throughout pregnancy [63]. As 
shown by the example from the US where NTD burden had 
fallen by 20% after mandatory fortification, recommenda-
tion alone, even without the economic constraint, is not 
likely to provide a feasible and effective solution [22]. Inter-
estingly, survey conducted in the UK found that there was 
only a marginal increase in folic acid intake in women who 
were planning pregnancy [64]. Additionally, around half of 
all pregnancies in the US are unexpected [58,62], and this 
figure may be even higher in LMIC where there may be lim-
ited availability of contraception.
Despite obvious benefits, before promoting folic acid for-
tification, many factors must be considered. Currently no 
country in the European Union has compulsory fortifica-
tion schemes due to risk consideration and campaigns 
Table 5. Studies that reported rates for the burden of spina 
bifida based on live births only
autHor aNd refereNCe sample size Cases rate(per 1000 live birtHs)
Aqrabawi [11] 5088 30 5.90
Asindi et al. [27] 82 176 46 0.56
Bademci et al. [28] 5499 11 2.00
Behrooz et al. [29] 13 262 23 1.73
Cherian et al. [31] 1218 6 4.93
Costa et al. [44] 9386 7 0.75
Khattak et al. [36] 5560 5 0.90
Mandiracioglu et al. [37] 36 331 43 1.18
Njamnshi et al. [38] 52 710 65 1.23
Petrova et al. [40] 141 159 147 1.04
Ricks et al. [42] 35 974 62 1.72
Safdar et al. [24] 33 489 36 1.07
Sayed et al. [25] 46 021 25 0.54
Yuskiv et al. [33] 75 609 29 0.38
Table 6. Studies that reported rates for the burden of anenceph-
aly based on live births only
autHor aNd refereNCe sample size Cases rate (per 1000 live birtHs)
Asindi et al. [27] 82 176 3 0.04
Behrooz et al. [29] 13 262 30 2.26
Cherian et al. [31] 1218 3 2.46
Costa et al. [44] 9386 1 0.11
Khattak et al. [36] 5560 63 11.33
Mandiracioglu et al. [45] 36 331 4 0.11
Njamnshi et al. [38] 52 710 4 0.08
Petrova et al. [40] 141 159 151 1.07
Ricks et al. [42] 35 974 10 0.28
Safdar et al. [24] 33 489 1 0.03
Sayed et al. [25] 46 021 17 0.37
Wasant et al. [43] 180 000 45 0.25
Yuskiv et al. [33] 75 609 1 0.01
Table 7. Studies that reported rates for the burden of encepalo-
cele based on live births only
autHor aNd refereNCe sample size Cases rate (per 1000 live birtHs)
Aqrabawi [11] 5 088 2 0.39
Asindi et al. [27] 82 176 15 0.18
Behrooz et al. [29] 13 262 3 0.23
Costa et al. [44] 9 386 3 0.32
Mandiracioglu et al. [45] 36 331 1 0.03
Njamnshi et al. [38] 52 710 5 0.09
Safdar et al. [24] 33 489 5 0.15
Wasant et al. [43] 180 000 14 0.08
Yuskiv et al. [33] 75 609 3 0.03
Table 8. Studies that reported rates for total NTD burden based 
on live births, stillbirths and terminations of pregnancy
autHor aNd refereNCe sample size Cases
rate (per 1000 live 
birtHs stillbirtHs 
aNd termiNatioNs)
Aguiar et al. [46] 18 807 89 4.73
Cortes et al. [32] 60 072 94 1.56
Cortes et al. [12] 486 779 419 0.86
Dai et al. [46] 2 281 616 2873 1.30
Golalipour et al. [47] 37 951 109 2.87
Golalipour et al. [12] 30 639 78 2.55
Golalipour et al. [48] 49 534 194 3.91
Gu et al. [13] 6420 128 19.94
Li et al. [10] 11 534 159 13.79
Liu et al. [49] 99 888 122 1.22
Mahadevan et al. [45] 54 738 310 5.66
Nazer et al. [50] 434 624 740 1.70
Noraihan et al. [51] 34 109 37 1.08
Onrat et al. [52] 8631 31 3.59
Rad et al. [53] 14 121 117 2.57
Yuskiv et al. [33] 75 928 159 2.09
Zhang et al. [54] 62 373 126 2.02
Table 9. Studies that reported rates for the burden of spina bifida 
based on live births, stillbirths and terminations of pregnancy
autHor aNd refereNCe sample size Cases rate (per 1000 live birtHs, 
stillbirtHs aNd termiNatioNs)
Cortes et al. [32] 60 072 46 0.77
Cortes et al. [12] 486 779 204 0.42
Golalipour et al. [47] 37 951 62 1.63
Golalipour et al. [12] 30 639 39 1.27
Gu et al. [13] 6420 25 3.89
Li et al. [10] 11 534 67 5.81
Liu et al. [49] 99 888 59 0.59
Mahadevan et al. [45] 54 738 170 3.11
Noraihan et al. [51] 34 109 12 0.35
Onrat et al. [52] 8631 9 1.04
Yuskiv et al. [33] 75 928 64 0.84
Aguiar et al. [55] 18 807 47 2.49
Dai et al. [46] 2 281 616 1369 0.60
Nazer et al. [50] 434 624 374 0.86
Rad et al. [53] 14 121 35 2.48
Table 10. Studies that reported rates for the burden of anencephaly 
based on live births, stillbirths and terminations of pregnancy
autHor aNd refereNCe sample size Cases rate (per 1000 live birtHs, 
stillbirtHs aNd termiNatioNs)
Aguiar et al. [55] 18 807 24 1.28
Cortes et al. [32] 60 072 37 0.62
Cortes et al. [12] 486 779 147 0.30
Dai et al. [46] 2 281 616 1140 0.50
Golalipour et al. [47] 37 951 43 1.40
Golalipour et al. [12] 30 639 35 0.92
Golalipour et al. [48] 49 534 56 1.13
Gu et al. [13] 6420 53 8.26
Li et al. [10] 11 534 75 6.50
Liu et al. [49] 99 888 42 0.42
Mahadevan et al. [45] 54 738 98 1.80
Nazer et al. [50] 434 624 311 0.72
Noraihan et al. [51] 34 109 25 0.73
Onrat et al. [52] 8631 12 1.39
Rad et al. [53] 14 121 78 5.52
Yuskiv et al. [33] 75 928 62 0.82
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against ‘mass medication’ [65,66]. Safety, ethics and eco-
nomic feasibility of a FAF programme must be taken into 
account before implementing such a policy, especially on 
a whole–country level. Nevertheless, current high burden 
of NTD in LMIC stresses the need for a comprehensive pre-
vention program.
For consistent and reliable estimates on burden of NTD, it is 
important to set up vital and birth registration documenta-
tion programs in countries that lack coherent information on 
NTD burden. Not only will this aid in the prevention and 
treatment of NTD, but it will also enable policy makers to 
monitor the benefits of implemented prevention programs. 
This may be particularly important for countries in the Afri-
can WHO region, where a high NTD burden is expected, but 
from which only a few studies have been published [67,68].
The reported NTD burden was estimated based on a lim-
ited number of available studies, some with very variable 
sample sizes that differed in inclusion of stillbirths and ter-
minated births in the study design. We could not use meta–
analysis, because studies came from such heterogeneous 
contexts that we didn't feel it was justified to present any-
thing beyond simple median and IQR in this initial estimate. 
This is partly because not all studies adhered to ICD–10 
classification of NTD and were not uniformly conducted 
regarding method of diagnosis and reporting of NTD type, 
enabling potential over– or under–estimation of NTD bur-
den through misdiagnosis. Also, the technical restrictions 
of accounting for all stillbirths and terminations in the ex-
amined studies limited the precision of our estimated bur-
den in that population [68].
Finally, the data was available from studies conducted in 
only 18 countries, implying that the studied sample is 
unlikely to be representative of all the LMIC globally. Re-
gardless of these significant limitations, it is our opinion 
that the estimated burdens reported in the results pro-
vide useful data for initial assessment of NTD burden in 
LMIC. An increase in high quality research on NTD, es-
pecially with regards to gender and geographical regions, 
should be prioritised to allow more accurate NTD esti-
mates. This would make the burden of the problem eas-
ier to estimate in a more credible way, and allow effective 
planning of prevention and intervention to minimise the 
risks for NTD.
Table 11. Studies that reported rates for the burden of encephalo-
cele based on live births, stillbirths and terminations of pregnancy
autHor aNd refereNCe sample size Cases
rate (per 1000 live 
birtHs stillbirtHs 
aNd termiNatioNs)
Aguiar et al. [55] 18 807 5 0.27
Cortes et al. [32] 60 072 11 0.18
Dai et al. [46] 2 281 616 365 0.16
Golalipour et al. [47] 37 951 4 0.11
Golalipour et al. [12] 30 639 4 0.13
Gu et al. [13] 6420 17 2.65
Li et al. [10] 11 534 17 1.47
Liu et al. [49] 99 888 7 0.07
Mahadevan et al. [45] 54 738 36 0.66
Nazer et al. [50] 434 624 91 0.21
Onrat et al. [52] 8631 2 0.23
Rad et al. [53] 14 121 4 0.28
Yuskiv et al. [33] 75 928 12 0.16
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